LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...

Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug ...

Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.

Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General ...

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing ...

Novo Holdings, the parent company of Novo Nordisk (NYSE:NVO), and Mubadala Investment are among Evotec’s other significant shareholders. "The combination of Halozyme and Evotec would diversify ...

Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects ...

Evotec's other major shareholders are Novo Nordisk (NOVOb.CO), opens new tab parent Novo Holdings and Mubadala Investment. "The combination of Halozyme and Evotec would diversify and extend ...

Earlier in the week, private equity firm Triton was reportedly considering a bid for Evotec after revealing it had acquired nearly a 10% stake in the company. Novo Holdings, the parent company of Novo ...

Evotec's other major shareholders are Novo Nordisk parent Novo Holdings and Mubadala Investment. "The combination of Halozyme and Evotec would diversify and extend Halozyme revenue and EBITDA growth ...

As part of the deal, Dewpoint can expect an undisclosed upfront payment from Mitsubishi Tanabe Pharma Corporation (MTPC) in ...

Evotec's other major shareholders are Novo Nordisk parent Novo Holdings and Mubadala Investment. Evotec's shares have fallen about 60% this year as revenues continue to slump due to weakness in ...